Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 3/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8217154 | 0.89 | — | — | |
| SCHEMBL483676 | 0.81 | CETP (0.49) | SMN1; SMN2CYP2C19CYP3A4P2RX7MME | |
| SCHEMBL4125078 | 0.81 | CYP2C19 (0.39) | SMN1; SMN2ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL15001823 | 0.80 | OPRL1 (0.33) | ALDH1A1 | |
| SCHEMBL24503904 | 0.79 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL5691429 | 0.76 | CETP (0.40) | SMN1; SMN2ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL12893372 | 0.76 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL1294518 | 0.75 | CYP4F2 (0.53) | SMN1; SMN2ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL12527553 | 0.74 | CETP (0.42) | SMN1; SMN2CYP2C19CYP3A4P2RX7MME | |
| SCHEMBL26665738 | 0.74 | CYP4F2 (0.35) | SMN1; SMN2CYP2C19CYP3A4P2RX7MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556117-B2 | Indole carboxamide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-31 | — | — | US | claimed |
| EP-2935211-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-09 | — | — | EP | claimed |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-03 | — | — | US | claimed |
| EP-3402469-B1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INST NAT SANTE RECH MED (FR) | 2021-01-06 | — | — | EP | disclosed |
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | INSERM (Institut National de la Santé et de la Recherche Médicale (FR) | 2020-02-04 | — | — | US | disclosed |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (FR) | 2019-01-24 | — | — | US | disclosed |
| EP-3402469-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017121840-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-07-20 | — | — | WO | disclosed |
| CN-104854087-B | Indole carboxamide derivatives as P2X receptor antagonists | 埃科特莱茵药品有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-9556117-B2 | Indole carboxamide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-31 | — | — | US | disclosed |
| EP-2935211-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-09 | — | — | EP | disclosed |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-03 | — | — | US | disclosed |
| EP-2935211-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014097140-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-26 | — | — | WO | disclosed |
| EP-2120846-A2 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | BASF SE (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008107347-A2 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | BASF SE (CH) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | P2RX7, P2RX1, P2RX5 | SMN1; SMN2 4035/4885ALDH1A1 2862/4885USP2 4445/4885 |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | SMN1; SMN2 4518/4885ALDH1A1 2019/4885USP2 4164/4885 |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | P2RX7, P2RX1, P2RX5 | SMN1; SMN2 4035/4885ALDH1A1 2862/4885USP2 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.